MIM
VIRX

Monashee Investment Management’s Viracta Therapeutics, Inc. Common Stock VIRX Stock Holding History

Monashee Investment Management’s Portfolio VIRX Stock Details VIRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q2 		– Sell
-84,802
Closed -$784K – 483
2021
Q1 		$784K Sell
84,802
-14,762
-15% -$154K 0.12% 199
2020
Q4 		$693K Buy
+99,564
New +$520K 0.09% 177

Other funds holding VIRX

BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
SB
Samsara BioCapital Palo Alto, California $1.03B AUM 214.94% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
SAM
Sectoral Asset Management Montreal, Quebec, Canada $121M AUM 73.47% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

Monashee Investment Management's VIRX Position: Q2 2021 in Review

Monashee Investment Management sold out of Viracta Therapeutics, Inc. Common Stock (VIRX) in Q2 2021, closing a stake of 84,802 shares — an estimated $784K sold.

Monashee Investment Management first reported a position in VIRX in Q4 2020 and held it in 2 quarters. The position peaked at $784K in Q1 2021. 63 funds tracked by Wall St. Rank hold VIRX as of Q2 2021.

  • Monashee Investment Management reported no remaining Viracta Therapeutics, Inc. Common Stock position as of Q2 2021 after selling out during the quarter.
  • Monashee Investment Management sold 84,802 Viracta Therapeutics, Inc. Common Stock shares in Q2 2021, an estimated $784K.
  • Monashee Investment Management first reported a position in Viracta Therapeutics, Inc. Common Stock in Q4 2020 and held it in 2 quarters.
  • Monashee Investment Management's Viracta Therapeutics, Inc. Common Stock position peaked at $784K in Q1 2021.
  • 63 funds tracked by Wall St. Rank held Viracta Therapeutics, Inc. Common Stock as of Q2 2021.

Based on Monashee Investment Management's 13F filing for Q2 2021, filed 12 Aug 2021.